Home
About Us
Company Overview
Mission
Leadship
Milestones
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
EN
中文
EN
Home
About Us
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
新闻中心
公司新闻
2025-10
2025
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity
2025-10-25
2025-10
2025
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)
2025-10-25
2025-10
2025
Sciwind Biosciences to present Data from its GLP-1 and GIP Receptor Agonist Programs at The International Liver Congress(TM) EASL 2022
2025-10-25
2025-10
2025
Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China
2025-10-25
2025-10
2025
Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China
2025-10-25
2025-10
2025
Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics
2025-10-20
2025-10
2025
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes
2025-10-20
2025-10
2025
Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity
2025-10-20
2025-10
2025
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China
2025-10-20
2025-10
2025
Sciwind Biosciences to Highlight Positive Clinical Data for GLP-1 Peptide Agonist Ecnoglutide (XW003) at the American Diabetes Association (ADA) 83rd Annual Conference
2025-10-20
<
1
2
3
4
>
